Who Paid My Doc
Farhad Zangeneh
Endocrinology, Diabetes & Metabolism Sterling, VA Medical Doctor
NPI 1114936937 CMS profile 277107
46090 Lake Center Plz, Suite 106, Sterling, VA 20165
General payments
$1,181,028
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Farhad Zangeneh of Sterling, VA is reported in the CMS Open Payments database as having received $1,181,028 across 1,896 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $126,692 | 170 | |
| 2024 | General | $95,212 | 162 | |
| 2023 | General | $91,230 | 174 | |
| 2022 | General | $246,664 | 340 | |
| 2021 | General | $136,023 | 205 | |
| 2020 | General | $176,691 | 296 | |
| 2019 | General | $308,516 | 549 |
Beside peers
- Farhad Zangeneh
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Farhad Zangeneh were reported at $126,692. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Farhad Zangeneh | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $308,516 | $494 | $123–$2,253 | $163 |
| 2020 | $176,691 | $335 | $85–$1,841 | $114 |
| 2021 | $136,023 | $398 | $88–$1,981 | $132 |
| 2022 | $246,664 | $364 | $88–$1,568 | $149 |
| 2023 | $91,230 | $420 | $113–$1,614 | $160 |
| 2024 | $95,212 | $440 | $121–$1,646 | $164 |
| 2025 | $126,692 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
1,879
Drug cost
$1,019,928
Branded share of claims
59.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 179 | $250,635 | |
| Mounjaro Tirzepatide | Brand | 115 | $132,151 | |
| Jardiance Empagliflozin | Brand | 87 | $114,001 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 67 | $78,451 | |
| Janumet Xr Sitagliptin Phos/Metformin Hcl | Brand | 50 | $74,994 | |
| Tymlos Abaloparatide | Brand | 16 | $61,062 | |
| Rybelsus Semaglutide | Brand | 51 | $55,987 | |
| Trulicity Dulaglutide | Brand | 34 | $38,680 | |
| Kerendia Finerenone | Brand | 22 | $25,039 | |
| Farxiga Dapagliflozin Propanediol | Brand | 25 | $23,773 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 9 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| MOUNJARO |
|
$47,754 | 115 | — |
| JARDIANCE |
|
$27,762 | 87 | — |
| Ozempic |
|
$6,702 | 179 | — |
| RYBELSUS |
|
$4,733 | 51 | — |
| Tirosint |
|
$64 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 9 in the dashboard with a free accountRecords
1,896 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Virginia
James Mulinda
Endocrinology, Diabetes & Metabolism · Roanoke, VA
Jeffrey Sicat
Endocrinology, Diabetes & Metabolism · Glen Allen, VA
Dewey Bailey
Endocrinology, Diabetes & Metabolism · Roanoke, VA
Domenica Rubino
Endocrinology, Diabetes & Metabolism · Arlington, VA
Samamtha Hudson
Endocrinology, Diabetes & Metabolism · Midlothian, VA
Elias Siraj
Endocrinology, Diabetes & Metabolism · Norfolk, VA
Related records
Endocrinology, Diabetes & Metabolism in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.